Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Robert Bradway named president and COO at Amgen

This article was originally published in Scrip

Executive Summary

Amgen has named Robert Bradway president and chief operating officer, effective 11 May. He will report to the company's chairman and CEO, Kevin Sharer, and will be responsible for global commercial operations, manufacturing operations, strategy & corporate development, IT, global government affairs and compliance. Mr Bradway has served as Amgen's executive vice-president and chief financial officer since April 2007, having joined the company in 2006 as vice-president of operations strategy. Before that, he was a managing director at Morgan Stanley in London, where he was responsible for the firm's banking department and corporate finance activities in Europe. Michael Kelly, Amgen's vice-president of finance and chief accounting officer, will serve as acting CFO, effective 11 May. He joined Amgen in 2003 and has served as chief accounting officer since 2005. Amgen also announced that its executive vice-president of global commercial operations, George Morrow, is to retire on 31 January 2011.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts